Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

• Published in: Molecular psychiatry Vol. 17; no. 12; pp. 1206 - 1227
• Main Authors: Miyamoto, S, Miyake, N, Jarskog, L F, Fleischhacker, W W, Lieberman, J A
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.12.2012; Nature Publishing Group
• Subjects: 631/92/609; 692/308/153; 692/699/476/1799; 692/700/565/1436; Adult and adolescent clinical studies; Animals; Antipsychotic Agents - adverse effects; Antipsychotic Agents - pharmacology; Antipsychotic Agents - therapeutic use; Antipsychotics; Behavioral Sciences; Biological and medical sciences; Biological Psychology; Chlorpromazine; Clozapine; Cognition & reasoning; Cognitive ability; Dopamine; Dopamine D2 receptors; Dosage and administration; Drug development; Drug Discovery - methods; Drug Discovery - trends; Drug therapy; Drugs; Endocrine disorders; feature-review; Health aspects; Humans; Medical sciences; Medicine; Medicine & Public Health; Mental disorders; Models, Neurological; Molecular Targeted Therapy - methods; Molecular Targeted Therapy - psychology; Neuroleptics; Neuropharmacology; Neuroprotection; Neurosciences; Neurotransmission; Patients; Pharmacology; Pharmacology. Drug treatments; Pharmacotherapy; Psychiatry; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Psychoses; Psychosis; Psychotropic drugs; Reviews; Schizophrenia; Schizophrenia - drug therapy; Side effects; Synaptic Transmission - drug effects; United States; New York; United States > US; antipsychotics; mechanism of action; add-on treatment; schizophrenia; cognition; negative symptoms; Neuroleptic; Psychotropic; Pharmacotherapy; Schizophrenia; Cognition; Review; Psychosis; Treatment; Negative symptom; Antipsychotic; Critical study; Mechanism of action
• ISSN: 1359-4184; 1476-5578
• DOI: 10.1038/mp.2012.47

Since the introduction of chlorpromazine and throughout the development of the new-generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been the target for the development of APDs. Pharmacologic actions to reduce neurotransmission through the D 2 receptor have been the only proven therapeutic mechanism for psychoses. A number of novel non-D 2 mechanisms of action of APDs have been explored over the past 40 years but none has definitively been proven effective. At the same time, the effectiveness of treatments and range of outcomes for patients are far from satisfactory. The relative success of antipsychotics in treating positive symptoms is limited by the fact that a substantial number of patients are refractory to current medications and by their lack of efficacy for negative and cognitive symptoms, which often determine the level of functional impairment. In addition, while the newer antipsychotics produce fewer motor side effects, safety and tolerability concerns about weight gain and endocrinopathies have emerged. Consequently, there is an urgent need for more effective and better-tolerated antipsychotic agents, and to identify new molecular targets and develop mechanistically novel compounds that can address the various symptom dimensions of schizophrenia. In recent years, a variety of new experimental pharmacological approaches have emerged, including compounds acting on targets other than the dopamine D 2 receptor. However, there is still an ongoing debate as to whether drugs selective for singe molecular targets (that is, ‘magic bullets’) or drugs selectively non-selective for several molecular targets (that is, ‘magic shotguns’, ‘multifunctional drugs’ or ‘intramolecular polypharmacy’) will lead to more effective new medications for schizophrenia. In this context, current and future drug development strategies can be seen to fall into three categories: (1) refinement of precedented mechanisms of action to provide drugs of comparable or superior efficacy and side-effect profiles to existing APDs; (2) development of novel (and presumably non-D 2 ) mechanism APDs; (3) development of compounds to be used as adjuncts to APDs to augment efficacy by targeting specific symptom dimensions of schizophrenia and particularly those not responsive to traditional APD treatment. In addition, efforts are being made to determine if the products of susceptibility genes in schizophrenia, identified by genetic linkage and association studies, may be viable targets for drug development. Finally, a focus on early detection and early intervention aimed at halting or reversing progressive pathophysiological processes in schizophrenia has gained great influence. This has encouraged future drug development and therapeutic strategies that are neuroprotective. This article provides an update and critical review of the pharmacology and clinical profiles of current APDs and drugs acting on novel targets with potential to be therapeutic agents in the future.